세계의 조제 약국 시장 : 제품별, 치료 영역별, 용도별, 컴파운딩 유형별, 무균성별, 유통 채널별 - 예측(2024-2032년)

Global Compounding Pharmacies Market will experience over 5.6% CAGR between 2024 and 2032, ushered by pharmaceutical innovation and research. Continuous R&D efforts have lead to the discovery of novel compounding techniques and customized medications, enhancing treatment options for patients with unique needs. According to the U.S. FDA report in January 2023, over 60% of new drug applications in 2022 involved innovative formulations, highlighting the significant role of ongoing pharmaceutical research in advancing compounding techniques and expanding opportunities for personalized medications.

These advancements enable pharmacists to create more effective, personalized formulations that address specific medical conditions, allergies, and dosage requirements. As new technologies and methods emerge, compounding pharmacies provide innovative solutions. The integration of cutting-edge research fosters trust among healthcare providers and patients, bolstering the demand for tailored medications.

The overall compounding pharmacies industry is classified based on product, therapeutic area, application, compounding type, sterility, distribution channel, and region.

The parental segment will witness a considerable CAGR through 2032, owing to the need for precise, tailored medications for infants and children. Standard dosages and formulations often do not suit this group, necessitating customized solutions. Compounding pharmacies can create specific dosage forms, such as liquids or transdermal gels, which are easier for children to ingest and absorb. Additionally, they can exclude allergens or intolerant substances, ensuring safety and efficacy. This personalization meets the unique medical needs of pediatric patients, ushering in the growing reliance on compounding pharmacies in the parental segment.

The hormone replacement segment will garner a noteworthy compounding pharmacies market share by 2032, because of the need for personalized hormone therapies that standard medications cannot provide. Patients often require specific hormone combinations and dosages tailored to their unique physiological needs, which compounding pharmacies can create. Additionally, they can formulate bio identical hormones, closely mimicking the body's natural hormones, improving treatment outcomes and reducing side effects. This customization enhances patient satisfaction and treatment efficacy, making compounding pharmacies an essential resource for effective hormone replacement therapy.

Europe compounding pharmacies market will thrive at a remarkable CAGR from 2024 to 2032, due to an increasing focus on personalized medicine and the need to address patient requirements that mass-produced drugs cannot meet. The upsurge in chronic illnesses and complex medical conditions necessitates customized drugs. Regulatory support for compounding practices, coupled with a heightened awareness among healthcare providers about the benefits of tailored treatments, fuels the demand. The aging population in the region, along with their need individualized & effective therapeutic solutions will augment the market growth in Europe.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising geriatric population and improved life expectancy across the globe
    • 3.2.1.2 Rising adoption of customized medicine in the developed regions
    • 3.2.1.3 Shortage of drugs across the globe
    • 3.2.1.4 Benefits of compounded medication
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of skilled lab technicians and pharmacists in developed economies
    • 3.2.2.2 High cost of equipment and maintenance of sterile environment
    • 3.2.2.3 Volatile regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
  • 3.4.3 Australia
• 3.5 Reimbursement landscape
  • 3.5.1 U.S.
  • 3.5.2 Europe
  • 3.5.3 Australia
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Oral
  • 5.2.1 Solid preparations
    • 5.2.1.1 Tablets
    • 5.2.1.2 Capsules
    • 5.2.1.3 Granules
    • 5.2.1.4 Powder
    • 5.2.1.5 Other solid preparations
  • 5.2.2 Liquid preparations
    • 5.2.2.1 Solutions
    • 5.2.2.2 Suspension
    • 5.2.2.3 Emulsion
    • 5.2.2.4 Syrup
    • 5.2.2.5 Other liquid preparations
• 5.3 Topical
  • 5.3.1 Ointments
  • 5.3.2 Creams
  • 5.3.3 Gels
  • 5.3.4 Pastes
  • 5.3.5 Other topical products
• 5.4 Rectal
  • 5.4.1 Suppositories
  • 5.4.2 Enema
  • 5.4.3 Other rectal products
• 5.5 Parenteral
  • 5.5.1 Large volume parenterals (LVPs)
  • 5.5.2 Small volume parenterals (LVPs)
• 5.6 Nasal
• 5.7 Ophthalmic
• 5.8 Otic

Chapter 6 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Pain management
• 6.3 Hormone replacement
• 6.4 Dermatology applications
• 6.5 Specialty drugs
• 6.6 Nutritional supplements
• 6.7 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Adult
• 7.3 Geriatric
• 7.4 Veterinary
• 7.5 Pediatric

Chapter 8 Market Estimates and Forecast, By Compounding Type, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Pharmaceutical ingredient alteration (PIA)
• 8.3 Currently unavailable pharmaceutical manufacturing (CUPM)
• 8.4 Pharmaceutical dosage alteration (PDA)
• 8.5 Other compounding types

Chapter 9 Market Estimates and Forecast, By Sterility, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Sterile dosage form
• 9.3 Non sterile dosage form

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Hospital pharmacies
• 10.3 Compounding pharmacies
• 10.4 Other distribution channels

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Poland
  • 11.3.7 Netherlands
  • 11.3.8 Sweden
  • 11.3.9 Belgium
  • 11.3.10 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
  • 11.4.6 Singapore
  • 11.4.7 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Argentina
  • 11.5.4 Rest of Latin America
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE
  • 11.6.4 Qatar
  • 11.6.5 Rest of Middle East and Africa

Chapter 12 Company Profiles

• 12.1 B. Braun Melsungen AG
• 12.2 Clinigen Group PLC
• 12.3 Dougherty's Pharmacy, Inc.
• 12.4 Fagron NV
• 12.5 Fresenius Kabi AG
• 12.6 ITC Compounding Pharmacy
• 12.7 Institutional Pharmacy Solutions, LLC
• 12.8 Lorraine's Pharmacy
• 12.9 McGuff Compounding Pharmacy Services
• 12.10 Nephron Pharmaceuticals Corporation
• 12.11 Pencol Compounding Pharmacy
• 12.12 Rx3 Compounding Pharmacy
• 12.13 Triangle Compounding Pharmacies
• 12.14 Valor Compounding Pharmacy, Inc.
• 12.15 Wedgewood Village Pharmacy, Inc.